EXAS Exact Sciences Corp
- Stocks
- Healthcare
- NASDAQ: EXAS
Price (delayed)
$68.87
Market cap
$13.05B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.35
Enterprise value
$14.78B
Relative Growth:
Rel. Growth:
42
Relative Strength:
Rel. Strength:
79
Relative Valuation:
Rel. Valuation:
14
Relative Profitability:
Rel. Profitability:
18
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first
Highlights
EXAS's gross profit is up by 14% year-on-year and by 4.7% since the previous quarter
EXAS's revenue is up by 14% year-on-year and by 4.8% since the previous quarter
The company's quick ratio rose by 26% YoY but it fell by 3.4% QoQ
The company's equity fell by 22% YoY
Key stats
What are the main financial stats of EXAS
Market
Valuations
Earnings
Shares outstanding
189.47M
Market cap
$13.05B
Enterprise value
$14.78B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.21
Price to sales (P/S)
4.23
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.8
Revenue
$3.08B
Gross profit
$2.08B
Operating income
-$1B
Net income
-$986.58M
EBIT
-$955.59M
EBITDA
-$710.69M
Free cash flow
$247.08M
Per share
Balance sheet
Liquidity
EPS
-$5.35
EPS diluted
-$5.35
Free cash flow per share
$1.31
Book value per share
$13.21
Revenue per share
$16.28
TBVPS
$13.69
Total assets
$5.9B
Total liabilities
$3.4B
Debt
$2.52B
Equity
$2.5B
Working capital
$1.01B
Debt to equity
1.01
Current ratio
2.72
Quick ratio
2.24
Net debt/EBITDA
-2.44
Margins
Efficiency
Dividend
EBITDA margin
-23.1%
Gross margin
67.4%
Net margin
-32%
Operating margin
-32.4%
Return on assets
-16.9%
Return on equity
-40.4%
Return on invested capital
-24.6%
Return on capital employed
-18%
Return on sales
-31%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXAS stock price
How has the Exact Sciences stock price performed over time
Intraday
-1.09%
1 week
8.94%
1 month
19.5%
1 year
25.86%
YTD
22.57%
QTD
25.88%
Financial performance
How have Exact Sciences's revenue and profit performed over time
Revenue
$3.08B
Gross profit
$2.08B
Operating income
-$1B
Net income
-$986.58M
Gross margin
67.4%
Net margin
-32%
EXAS's gross profit is up by 14% year-on-year and by 4.7% since the previous quarter
EXAS's revenue is up by 14% year-on-year and by 4.8% since the previous quarter
The company's net margin rose by 6% QoQ
The operating margin has increased by 6% since the previous quarter
Price vs fundamentals
How does EXAS's price correlate with its fundamentals
Growth
What is Exact Sciences's growth rate over time
Valuation
What is Exact Sciences stock price valuation
P/E
N/A
P/B
5.21
P/S
4.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.8
Exact Sciences's EPS has increased by 2% from the previous quarter
The stock's price to book (P/B) is 32% more than its last 4 quarters average of 4.0 and 25% more than its 5-year quarterly average of 4.2
The company's equity fell by 22% YoY
EXAS's price to sales (P/S) is 31% less than its 5-year quarterly average of 6.2 but 30% more than its last 4 quarters average of 3.3
EXAS's revenue is up by 14% year-on-year and by 4.8% since the previous quarter
Efficiency
How efficient is Exact Sciences business performance
Exact Sciences's ROS has increased by 7% from the previous quarter
The ROE has contracted by 5% from the previous quarter
Dividends
What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXAS.
Financial health
How did Exact Sciences financials performed over time
The total assets is 74% more than the total liabilities
EXAS's current ratio is up by 28% YoY but it is down by 6% QoQ
The company's quick ratio rose by 26% YoY but it fell by 3.4% QoQ
The company's equity fell by 22% YoY
EXAS's debt to equity is up by 17% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.